



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8049)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2019

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the "Directors") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiary ("the Group"). The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

UNAUDITED INTERIM RESULTS

The directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited ("the Company") are pleased to announce the unaudited consolidated financial statements of the Company and its subsidiaries (the "Group") for the six months and three months ended 30 June 2019 together with the comparative figures for the corresponding periods in 2018 as follows:

CONDENSED CONSOLIDATED INCOME STATEMENT (UNAUDITED)

For the six months and three months ended 30 June 2019 and 30 June 2018

		Six months ended 30 June		Three months ended 30 June	
	Note	2019 (Unaudited) RMB'000	2018 (Unaudited) RMB'000	2019 (Unaudited) RMB'000	2018 (Unaudited) RMB'000
Turnover	4	299,404	312,070	158,443	151,563
Cost of sales		(50,478)	(55,548)	(27,914)	(28,328)
Gross profit		248,926	256,522	130,529	123,235
Other revenue	4	21,007	16,383	13,613	11,442
Distribution and selling costs		(182,650)	(194,606)	(87,613)	(85,677)
Administrative expenses		(24,298)	(12,809)	(11,603)	(5,823)
Profit from operations	6	62,985	65,490	44,926	43,177
Finance costs		(63)	(93)	(30)	(67)
Profit before taxation		62,922	65,397	44,896	43,110
Taxation	7	(9,449)	(9,875)	(6,684)	(6,493)
Profit attributable to equity holders of the Company		53,473	55,522	38,212	36,617
Earnings per share – Basic	8	9.54 cents	9.91 cents	6.82 cents	6.54 cents
Dividends	9	–	–	–	–

Note: Calculation of the earnings per share in 2018 and 2019 was based on 560,250,000 shares and 560,250,000 shares respectively.

CONDENSED CONSOLIDATED BALANCE SHEET

As at 30 June 2019 and 31 December 2018

		30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
	Note		
Assets and liabilities			
Non-current assets			
Bearer biological assets	10	11,709	11,745
Property, plant and equipment	11	149,129	156,591
Prepaid lease payments	12	15,068	15,068
Construction in progress	13	68,135	67,588
Intangible assets	14	–	–
Deferred tax assets		934	944
Total non-current assets		244,975	251,936
Current assets			
Inventories	15	52,329	52,456
Trade receivables	16	276,343	249,326
Contract assets		45,309	45,309
Other receivables, deposits and prepayments		246,110	225,408
Prepaid lease payments	12	–	454
Financial assets at fair value through profit or loss		561,612	571,612
Cash and cash equivalents		148,617	158,340
Total current assets		1,330,320	1,302,905
Current liabilities			
Trade payables	17	22,103	31,705
Contract liabilities		14,779	14,779
Other payables, deposits received and accruals		250,105	280,446
Deferred income		312	589
Income tax payable		16,999	20,645
Other tax payables		27,372	16,754
Loans from government authority		1,240	1,240
Dividend payable		8,862	9,326
Total current liabilities		341,772	375,484
Net current assets		988,548	927,421
Total assets less current liabilities		1,233,523	1,179,357
Non-current liabilities			
Loan from government authority		1,110	1,110
Deferred income		45,170	45,170
Deferred tax liabilities		746	52
		47,026	46,332
Net assets		1,186,497	1,133,025
Equity:			
Share capital	18	56,025	56,025
Reserves		1,130,472	1,077,000
Total equity		1,186,497	1,133,025

CONDENSED CONSOLIDATED CASH FLOW STATEMENT (UNAUDITED)

For the six months ended 30 June 2019 and 30 June 2018

	For the six months ended	
	30 June 2019	30 June 2018
	RMB'000	RMB'000
Net cash inflow from/(outflow to) operating activities	47,214	(40,675)
Net cash outflow to investing activities	(57,623)	(924)
Decrease in cash and cash equivalents	(10,409)	(41,599)
Cash and cash equivalents at beginning of the period	159,026	200,625
Cash and cash equivalents at end of the period	148,617	159,026
Analysis of balances of cash and cash equivalents		
Cash and bank balances	148,617	159,026

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the six months ended 30 June 2019 and 30 June 2018

	PRC statutory funds				
	Share capital	Share premium	Statutory surplus reserve	Retained profits	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2018 (Audited)	56,025	51,098	33,242	870,662	1,011,027
Net profit for the six months ended 30 June 2018 (Unaudited)	—	—	—	55,522	55,522
At 30 June 2018 (Unaudited)	56,025	51,098	33,242	926,184	1,066,549
Net profit for the six months ended 31 December 2018 (Unaudited)	—	—	—	105,694	105,694
Dividends paid	—	—	—	(39,218)	(39,218)
Balance as at 31 December 2018 (Audited)	56,025	51,098	33,242	992,660	1,133,025
Net profit for the six months ended 30 June 2019 (Unaudited)	—	—	—	53,472	53,472
At 30 June 2019 (Unaudited)	56,025	51,098	33,242	1,046,132	1,186,497

NOTES TO CONDENSED INTERIM ACCOUNTS:

1. ORGANISATION AND OPERATIONS

The Company was established as a state-owned enterprise in the People's Republic of China (the "PRC") in 1989. On 29 December 1995, under the relevant provisions of the Company Law of the PRC, the Company was re-organized from a state-owned enterprise to a limited liability company. On 16 August 1996, with the approval of the Economic Restructuring Commission of Jilin Province, the Company was further converted into a joint stock limited company. On 20 April 1999, the Company made a bonus issue from capitalisation of retained profits at the proportion of one bonus share for every two existing shares. The Company's H shares were listed on the GEM of the Stock Exchange of Hong Kong Limited on 24 May 2001.

The Group is principally engaged in the manufacture and distribution of biochemical medicines in the PRC under the brandnames of Changlong and Shendi.

2. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The unaudited condensed consolidated financial statements have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRSs"), which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and interpretations issued by Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance.

The unaudited condensed consolidated financial statements have been prepared under the historical cost convention, as modified for the revaluation of financial instruments which have been measured at fair value.

The accounting policies adopted in preparing the unaudited condensed consolidated financial statements for the period under review are consistent with those followed in the Company's 2018 annual report.

The condensed consolidated financial statements for the six months ended 30 June 2019 are unaudited and have been reviewed by the audit committee of the Company.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The adoption of the new and revised Hong Kong Financial Reporting Standards ("HKFRSs") effective as of 1 January 2019 are as follows:

Amendments to HKFRS 9	<i>Prepayment Features with Negative Compensation</i>
HKFRS 16	<i>Leases</i>
Amendments to HKAS 19	<i>Plan Amendment, Curtailment or Settlement</i>
Amendments to HKAS 28	<i>Long-term Interests in Associates and Joint Ventures</i>
HK(IFRIC)-Int 23	<i>Uncertainty over Income Tax Treatments</i>
<i>Annual Improvements</i>	Amendments to HKFRS 3, HKFRS 11, HKAS 12
<i>2015-2017 Cycle</i>	and HKAS 23

The adoption of the above new and revised HKFRSs has had no significant financial effect on the interim condensed consolidated financial statements of the Group.

4. TURNOVER AND REVENUE

The Group's turnover comprises the invoiced value of merchandise sold net of value – added tax and after allowances for returns and discounts.

	Six months ended		Three months ended	
	30 June		30 June	
	2019	2018	2019	2018
	RMB'000	RMB'000	RMB'000	RMB'000
Turnover				
Sales of medicine	299,404	312,070	158,443	151,563
Other revenue				
Other income	21,007	16,383	13,613	11,442
Total revenue for the year	320,411	328,453	172,056	163,005

5. SEGMENT INFORMATION

The Group has only one business segment which is in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC. For the six months ended 30 June 2019, turnover of the Group is generated entirely from sales in the PRC and all identifiable assets of the Group are located in PRC. Accordingly, no business or geographical segmental analysis is prepared for the period.

6. PROFIT FROM OPERATIONS

The Group's profit from operations is arrived at after charging:

	Six months ended		Three months ended	
	30 June		30 June	
	2019	2018	2019	2018
	RMB'000	RMB'000	RMB'000	RMB'000
Depreciation	10,638	16,716	5,319	8,358
Amortisation of intangible asset	<u>—</u>	<u>—</u>	<u>—</u>	<u>—</u>

7. TAXATION

Taxation in the unaudited condensed consolidated income statement represents:

	Six months ended		Three months ended	
	30 June		30 June	
	2019	2018	2019	2018
	RMB'000	RMB'000	RMB'000	RMB'000
PRC income tax	<u>9,449</u>	<u>9,875</u>	<u>6,684</u>	<u>6,493</u>

The PRC income tax is computed according to the relevant laws and regulations in the PRC. The applicable income tax rate was 15% (2018: 15%).

The Group did not have any significant unprovided deferred taxation for the six months and three months ended 30 June 2019 (2018: Nil).

8. EARNINGS PER SHARE

The calculation of basic earnings per share for the six months and three months ended 30 June 2019 is based on the unaudited profit attributable to shareholders of approximately RMB53,473,000 and RMB38,212,000 respectively (2018: RMB55,522,000 and RMB36,617,000) and on the weighted average of 560,250,000 and 560,250,000 (2018: 560,250,000 and 560,250,000) shares in issue during the two period ended 30 June 2019 respectively.

There is no diluted earnings per share because there were no dilutive potential shares in existence during the relevant periods.

9. DIVIDENDS

The Board does not recommend the payment of an interim dividend for the six months ended 2019 (2018: Nil).

10. BEARER BIOLOGICAL ASSETS

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Ginseng	<u>11,709</u>	<u>11,745</u>

11. PROPERTY, PLANT AND EQUIPMENT

The movements of property, plant and equipment of the Group were:

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Net book value, beginning of period/year	156,591	166,133
Additions & Disposals & Transfer from construction in progress	3,176	9,797
Depreciation & Written back on disposals	(10,638)	(19,339)
	149,129	156,591

12. PREPAID LEASE PAYMENTS

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Net book value, beginning of period/year	15,522	15,974
Amortisation	(454)	(454)
	15,068	15,522
Net book value, end of period/year	15,068	15,522
Net book value at end of period/year	15,068	15,522
Portion classified as current assets	–	(454)
	15,068	15,068

The Group's medium-term land use rights are located in the PRC.

13. CONSTRUCTION IN PROGRESS

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Net book value, beginning of period/year	67,588	44,127
Additions	537	23,461
Transfer to property, plant and equipment	—	—
Net book value, end of period/year	<u>68,125</u>	<u>67,588</u>

14. INTANGIBLE ASSETS

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Cost:		
At 1 January	68,135	67,975
Additions & Disposal	—	160
At 30 June 2019/31 December 2018	<u>68,135</u>	<u>68,135</u>
Accumulated amortization and impairment loss:		
At 1 January	68,135	67,975
Impairment for the period/year	—	160
At 30 June 2019/31 December 2018	<u>68,135</u>	<u>68,135</u>
Net book value:		
At 30 June 2019/31 December 2018	<u>—</u>	<u>—</u>

Purchased know-how and prescription were all acquired by cash from independent third parties.

15. INVENTORIES

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Inventories comprise:		
At cost:		
Raw materials	30,566	18,607
Work in progress	18,083	29,462
Finished goods	6,098	6,805
	54,747	54,874
Less: provision for obsolete and slow-moving inventories	(2,418)	(2,418)
	52,329	52,456

As at 30 June 2019, inventories amounting to approximately RMB52,329,000 (2018: RMB52,456,000) were carried at net realizable value.

16. TRADE RECEIVABLES

Trade receivables are stated at cost less provision for doubtful debts. Provisions for doubtful debts are made based upon the directors' knowledge of the customers, the creditworthiness and settlement history, and the aging of the outstanding trade receivables.

The following is an aged analysis of trade receivables, net of provision for impairment for trade receivables, at the balance sheet dates:

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Current	66,414	59,921
31-90 days	73,271	66,108
91-180 days	78,806	71,102
More than 180 days	57,852	52,195
	<u>276,343</u>	<u>249,326</u>

The directors consider the carrying amount of trade receivables approximates their fair value.

17. TRADE PAYABLES

The following is an aged analysis of trade payables at the balance sheet dates:

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Current	3,060	4,390
31-90 days	2,494	3,578
More than 90 days	16,549	23,737
	<u>22,103</u>	<u>31,705</u>

Trade payables principally comprise amounts outstanding for trade purchases. The directors consider that the carrying amount of trade payables approximates their fair value.

18. SHARE CAPITAL

	Number of shares	30 June 2019 (Unaudited) RMB'000	Number of shares	31 December 2018 (Audited) RMB'000
Domestic shares of RMBO.10 each	387,750,000	38,775	387,750,000	38,775
H shares of RMBO.10 each	172,500,000	17,250	172,500,000	17,250
	<u>560,250,000</u>	<u>56,025</u>	<u>560,250,000</u>	<u>56,025</u>

19. CAPITAL COMMITMENTS

As at 30 June 2019, the Group had capital commitments contracted for but not provided for in respect of the following:

	30 June 2019 (Unaudited) RMB'000	31 December 2018 (Audited) RMB'000
Acquisition of intangible assets	1,750	1,750
Acquisition of property, plant and equipment	—	171
	<u>1,750</u>	<u>1,921</u>

MANAGEMENT DISCUSSION AND ANALYSIS

OPERATING RESULTS

For the six months ended 30 June 2019, the Group recorded a turnover of approximately RMB299,404,000, representing an decrease of 4% from RMB312,070,000 for the corresponding period in 2018. Profit attributable to shareholders for the six months ended 30 June 2019 was RMB53,473,000, representing an decrease of RMB2,049,000 from RMB55,522,000 for the corresponding period in 2018.

The gross profit margin for the six months ended 30 June 2019 was approximately 83.1% representing a 0.9% increase as compared to that of 82.2% for the period ended 30 June 2018. The Board believes that there were no significant fluctuation for the production and material cost.

The selling expense as a percentage of turnover was 61% in 2019. This represented an decrease from 62.3% when compared to the same period last year. General and administrative expenses increase from RMB12,809,000 for the six months ended 30 June 2018 to RMB24,298,000 for the same period in 2019.

BUSINESS REVIEW

Production Facilities

During the year, the purchase and setting up of equipment and testing works of 吉林長龍食品飲料有限責任公司, a wholly-owned subsidiary, have completed and the accreditation of food production has passed and we launched the product of Changbai Mountain wild walnuts milk. With the continued development of pharmaceutical healthcare field, Changlong Bio-pharmacy improve pharmaceutical research and development continuously while investing in research and development of food and healthcare field in order to provide better service to our people and benefit human kind, providing a new profit driver for the enhancement of the Group's result.

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position during this period. For the six months ended 30 June 2019, the Group's primary source of funds was cash from the operating activities. As at 30 June 2019, the Group had cash and bank balances and consolidated net asset value of approximately RMB148,617,000 and RMB1,186,497,000 respectively.

For the six months ended 30 June 2019, the Group mainly generated revenue and incurred costs in Hong Kong dollars and Renminbi. The Directors consider the impact on foreign exchange exposure of the Group is minimal.

As at 30 June 2019, the Group had no material contingent liabilities.

GEARING RATIO

As at 30 June 2019, the Group had short-term bank borrowings of RMB Nil (2018: RMB Nil) and a gearing ratio of approximately 0%. The calculation of the gearing ratio was based on the short-term bank loans and shareholders' equity as at 30 June 2019.

CAPITAL COMMITMENTS

Details of the capital commitments of the Company as at 30 June 2019 are set out in note 19 to the financial statement.

CAPITAL STRUCTURE

During the six months ended 30 June 2019, there was no change in the Company's share capital. As at 30 June 2019, the Group's operations were financed mainly by shareholders' equity. The Group will continue to adopt its treasury policy of placing the Group's cash and cash equivalents in interest bearing deposits, and to fund the operation with internal resources.

FUTURE PROSPECTS

There has been an increase in the Group's turnover and profit attributable to equity holders of the Company as compared with the same period last year.

The Directors would like to take this opportunity to express their gratitude to the management and staff for their dedication and contribution to the Group, and to thank our fellow business partners and equity holders for their continuing support. The Directors will endeavor to explore every potential opportunity for business growth, creating a promising future and successful results in the years ahead.

DIRECTORS' INTERESTS IN SHARES

At 30 June 2019, the interests and short positions of the Directors, supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO") as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules were as follows:

Long positions in shares

Director	Type of Interests	Capacity	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital
Mr. Zhang Hong	Personal	Beneficial owner	101,937,000	26.29	18.19
Mr. Zhang Xiao Guang	Personal	Beneficial owner	42,315,000	10.91	7.55
Mr. Wu Guo Wen	Personal	Beneficial owner	900,000	0.232	0.161

Save as disclosed above, as at 30 June 2019, none of the Directors, supervisors and chief executives of the Company has any interests and short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules.

DIRECTORS' RIGHTS TO ACQUIRE SHARES

Apart from as disclosed under the headings "Directors' interests in shares" above, at no time during the period were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any director and chief executives or their respective spouses or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company, or any of its subsidiaries a party to any arrangement to enable the directors, supervisors and chief executives to acquire such rights in any other body corporate.

INTERESTS DISCLOSEABLE UNDER THE SFO AND SUBSTANTIAL SHAREHOLDERS

As at 30 June 2019, the following persons (other than the Directors, supervisors and chief executives of the Company) had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

Long positions in shares

Name of shareholder	Capacity/Nature of Interest	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital
Huinan County SAB (Note)	Beneficial owner	81,975,000	21.14	14.63

Note: Apart from the equity interest in the Company, Huinan County SAB does not have any direct or indirect interest in the Company, including representation in the Board of Directors.

Save as disclosed above, as at 30 June 2019, the Directors were not aware of any other person (other than the Directors, supervisors and chief executives of the Company) who had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

Long positions in H shares

Name of shareholder	Capacity	Number of H Shares	Percentage of H Shares	Percentage of total registered Share Capital
Chen Jingwei	Beneficial owner	29,520,000	17.11%	5.269%
Shen Qianzhen	Beneficial owner	13,996,000	8.11%	2.498%

COMPETING INTEREST

During the period under review, none of the Directors, the management shareholders, the significant shareholders or the substantial shareholders (as defined in the GEM Listing Rules) of the Company had any interest in a business, which competes or may compete with the business of the Group.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the six months ended 30 June 2019, the Company has adopted a code of conduct regarding securities transactions by directors on terms no less than the required standard of dealings as set out in rules 5.48 to 5.67 of the GEM Listing Rules. The Company has also made specific enquiry of all Directors and the Company was not aware of any non-compliance with the required standard of dealings and its code of conduct regarding securities transactions by Directors.

BOARD PRACTICES AND PROCEDURES

During the period under review, the Company had not fully complied with the board practices and procedures as set out in Rules 5.34 of the GEM Listing Rules in respect of the Code on Corporate Governance Practices (the "CCGP"). The main deviations from the code provision set out in the CCGP were as follows:

Under the code provision A.2.1, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Zhang Hong assumes the role of both the chairman and the chief executive officer of the Company. The Board is of the view that this has not compromised accountability and independent decision making for the following reasons:

- the Audit Committee composes exclusively of independent non-executive directors;
- the independent directors have free and direct access to the Company's external auditors and independent professional advice when considered necessary.

Mr. Zhang Hong, the chairman, is a substantial shareholder of the Company and has considerable industry experience. He is motivated to contribute to the growth and profitability of the Group. The Board is of the view that it is in the best interests of the Group to have an executive chairman so that the Board can have the benefit of a chairman who is knowledgeable about the business of the Group and is most capable to guide discussions and brief the Board in a timely manner on pertinent issues and developments to facilitate open dialogue between the Board and the management.

AUDIT COMMITTEE

The Company set up an audit committee (the "Committee") on 24 May 2001 with written terms of reference in compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The audit committee comprise three independent non executive directors, namely Gao Yong Cai, Gao Qi Pin and Tian Jie, Gao Yong Cai is the Chairman of the audit committee. The primary duties of the Committee are to review and provide supervision over the financial reporting procedures and internal control system of the Group.

The committee has reviewed with the management the accounting principles and practices adopted by the Group and discussed internal controls and financial reporting matters, including a review of the unaudited results of the Group for the period ended 30 June 2019.

EMPLOYEES AND REMUNERATION POLICIES

As at 30 June 2019, the Group had 870 employees (30 June 2018: 520 employees). Remuneration is determined by reference to market terms and the performance, qualifications and experience of individual employee. Discretionary bonuses based on individual performance will be paid to employees as recognition of and reward for their contribution. Other benefits include contributions to retirement scheme and medical scheme.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES

During the six months ended 30 June 2019, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company's listed shares.

By order of the Board
Zhang Hong
Chairman

Jilin, the PRC
14 August 2019

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Yong Cai, Gao Qi Pin and Tian Jie.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for 7 days from the day of its posting.